Loading...
01/11 03:08
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals: strong revenue growth in Q4 2024 and positive free cash flow, but financial losses and dependency on Johnson & Johnson pose risks. The Q&A shows uncertainty in revenue guidance and regulatory approvals, with vague responses from management. The lack of shareholder return plans and the company's financial strain further balance the positive aspects, resulting in a neutral sentiment.
Revenue for Q4 2024 $6,300,000, a 39% increase from $4,600,000 in Q4 2023.
System Revenue for Q4 2024 $1,400,000, compared to $100,000 in Q4 2023.
Recurring Revenue for Q4 2024 $4,900,000, compared to $4,500,000 in Q4 2023, reflecting a full quarter’s contribution from the acquisition of APT.
Revenue for Full Year 2024 $26,900,000, compared to $26,800,000 in 2023.
Full Year System Revenue $8,600,000, compared to $8,700,000 in the prior year.
Full Year Recurring Revenue $18,300,000, compared to $18,000,000 in 2023, with continued catheter shortages offset by the contribution of APT.
Gross Margin for Q4 2024 Approximately 51-54% of revenue.
Full Year Recurring Revenue Gross Margin 70%.
Full Year System Gross Margin 20%.
Operating Expenses for Q4 2024 $10,800,000, including $2,500,000 in noncash stock compensation and a $1,100,000 noncash mark to market adjustment.
Adjusted Operating Expenses for Full Year 2024 $27,400,000, compared to $26,200,000 in the prior year.
Operating Loss for Q4 2024 $7,600,000, compared to $5,300,000 in Q4 2023.
Net Loss for Q4 2024 $7,500,000, compared to $5,000,000 in Q4 2023.
Adjusted Operating Loss for Q4 2024 $4,000,000, compared to $2,700,000 in Q4 2023.
Adjusted Net Loss for Q4 2024 $3,800,000, compared to $2,400,000 in Q4 2023.
Free Cash Flow for Q4 2024 Positive $1,300,000.
Free Cash Flow for Full Year 2024 Negative $8,500,000, compared to negative $9,500,000 in 2023.
Cash and Cash Equivalents at December 31, 2024 $12,400,000, with no debt.
Magic Ablation Catheter: Received European CE Mark approval; first sales expected in March, targeting $1,000,000 revenue per quarter by year-end.
Magic Sweep Catheter: Regulatory submission completed; expected approvals in Europe and U.S. by Q3, with similar revenue potential to Magic Ablation.
Imagen 5F Catheter: First vascular catheter submission to FDA; expected approvals in Q3, with modest short-term revenue but significant strategic value.
Genesis X Robot: CE Mark received; U.S. regulatory submission in progress; first commercial launch in Europe expected this summer.
China Market Expansion: Partner MicroPort received regulatory approval for Genesis robot and related systems; significant opportunity in the Chinese EP market.
Operational Efficiencies: Acquisition of APT enhanced catheter development capabilities; ongoing efforts to streamline manufacturing and supply chain.
Strategic Transformation: Focus on four pillars: robot accessibility, catheter ecosystem, interventional device development, and AI connectivity in cath labs.
Regulatory Risks: The company faces regulatory scrutiny from the FDA regarding its submissions for the MAGIC catheter and the Genesis X robot, with specific concerns raised about cybersecurity and the need for potential audits of manufacturing facilities.
Supply Chain Challenges: Stereotaxis is experiencing dependencies on Johnson and Johnson for catheter supplies, which has caused operational stress and limited innovation.
Market Competition: The company is shielded from competitive dynamics in the cardiac ablation market due to its focus on complex arrhythmias, but the overall market dynamics are distracting for customers.
Economic Factors: In China, the macroeconomic environment and anti-corruption campaigns pose significant headwinds for commercial efforts, despite a strong pipeline of interested hospitals.
Operational Risks: The company has structural limitations that have historically hindered its growth, including a lack of developed catheters for robotic procedures, which they are now addressing through strategic innovations.
Financial Risks: The company reported a negative cash flow of $8,500,000 for the full year 2024, indicating potential financial strain as they continue to invest in product development and regulatory approvals.
Strategic Transformation: Stereotaxis is undergoing a major strategic transformation to improve endovascular surgery with robotics, aiming to become a leader in minimally invasive interventions.
Four Pillars of Strategy: 1. Make the robot widely available with rapid installation. 2. Build an ecosystem of catheters to reduce dependencies. 3. Develop interventional devices for broader applications. 4. Introduce connectivity and AI to enhance the robot's capabilities.
Acquisition of APT: The acquisition of APT has advanced catheter development and manufacturing capabilities, complementing Stereotaxis' robotic expertise.
Regulatory Milestones: Key regulatory submissions include the Genasys X robot and the Magic Ablation catheter, with expectations for approvals in the U.S. and Europe.
Expansion into China: Stereotaxis is partnering with MicroPort to commercialize its technology in China, targeting a large market with significant potential.
2025 Revenue Guidance: Expected system revenue of $2,000,000 to $3,000,000 per quarter, with a flat overall revenue compared to 2024.
Recurring Revenue Growth: Anticipated growth in recurring revenue from $5,000,000 in Q1 to $7,000,000 in Q4 of 2025.
Long-term Growth Outlook: Expectations for double-digit annual growth in 2025, with substantial growth anticipated in 2026.
Magic Catheter Revenue: Projected to generate approximately $1,000,000 per quarter in Europe by the end of 2025.
Cash Flow Expectations: Reduced cash use expected in 2025, with a focus on maintaining flat operating expenses.
Shareholder Return Plan: Stereotaxis has not announced any specific share buyback program or dividend program during the call. The focus was primarily on product launches and regulatory approvals.
The earnings call presented mixed signals: while product development with GenesisX and new catheters is promising, financials show consistent losses and a negative cash flow. The Q&A reveals a cautious approach to new launches and regulatory approvals, indicating uncertainty. No strong catalysts like partnerships or guidance changes were mentioned. Therefore, the stock is likely to remain stable in the short term.
The earnings call presents mixed signals: while product development and business updates show promise, especially in Europe, financial performance is concerning with declining system revenue and increasing operating losses. The Q&A reveals positive reception of new products but highlights uncertainties in U.S. regulatory approvals and market adoption challenges. The lack of a share repurchase program and structural challenges further dampen sentiment. Overall, the mixed guidance and financials, coupled with regional uncertainties, suggest a neutral stock price movement.
Despite a 39% increase in Q4 revenue, operating losses have widened, and there are significant supply chain challenges. The absence of a share repurchase program and conservative guidance further dampen sentiment. While there are promising product developments, regulatory and market uncertainties, especially in China, pose risks. The Q&A session highlighted management's inability to provide clear timelines for key product approvals, adding to investor concerns. Overall, the negative financial indicators and uncertainties outweigh the positive revenue growth.
The earnings call reveals mixed signals: strong revenue growth in Q4 2024 and positive free cash flow, but financial losses and dependency on Johnson & Johnson pose risks. The Q&A shows uncertainty in revenue guidance and regulatory approvals, with vague responses from management. The lack of shareholder return plans and the company's financial strain further balance the positive aspects, resulting in a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
